Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial

BACKGROUND: Although mass vaccination has reduced the severity of COVID-19, mortality is still high among hospitalized patients. Being a sepsis-like disease, an anti-inflammatory drug as atorvastatin would reduce mortality and severity in COVID-19. METHODS: We designed a randomized clinical trial th...

Descripción completa

Detalles Bibliográficos
Autores principales: Emara, Moataz Maher, Elsawy, Neamat Hamdy, Abdelaaty, Kholoud M., Elhamaky, Amal Salah, Eltahan, Naglaa Hamdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360729/
https://www.ncbi.nlm.nih.gov/pubmed/35941669
http://dx.doi.org/10.1186/s13063-022-06619-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360729/
https://www.ncbi.nlm.nih.gov/pubmed/35941669
http://dx.doi.org/10.1186/s13063-022-06619-9

Ejemplares similares